NYSEMKT — Healthcare: Manufacturing, Biotechnology: Biological Products (No Disgnostic Substances)
www.lineagecell.comLineage Cell Therapeutics will present 36-month results from the Phase 1/2a clinical study of RG6501 (OpRegen), an allogeneic retinal pigment epithelium (RPE) cell therapy for geographic atrophy secondary to age-related macular degeneration (AMD), at the Clinical Trials at the Summit 2025 on June 21, 2025. The data will be presented by Dr. Christopher D. Riemann on behalf of Roche and Genentech, Lineage's collaborators. OpRegen is being developed as a potential one-time treatment for dry AMD, aiming to address unmet needs in this indication.
clinical readoutLineage Cell Therapeutics, in partnership with the Christopher & Dana Reeve Foundation, will host the 3rd Annual Spinal Cord Injury Investor Symposium (SCIIS) virtually starting June 27, 2025. The event will feature interactive and on-demand sessions focused on treatments for spinal cord injury, bringing together regulators, key opinion leaders, advocacy organizations, and investors. The symposium aims to discuss current and future SCI therapies, promote disease awareness, and encourage clinical trial participation and investment in the sector. Lineage is developing OPC1, an allogeneic cell therapy for spinal cord injury, and OpRegen, a cell therapy for age-related macular degeneration.
conference talkLineage Cell Therapeutics and the Reeve Foundation will host a fully virtual symposium on June 27, 2025, focusing on spinal cord injury treatments and fostering investment in innovative research.
conference talkLineage Cell Therapeutics is expected to complete its long-term follow-up (LTFU) study NCT05919563 on December 12, 2026. The Phase 1 trial monitors the long-term safety of GRNOPC1, an oligodendrocyte progenitor cell therapy, in five subjects with complete thoracic spinal cord injury (SCI) who received the therapy in a prior study. The study aims to provide 15 years of post-administration safety data for GRNOPC1, a cell-based regenerative medicine product targeting spinal cord injury.
trial completionLineage Cell Therapeutics is conducting a long-term follow-up (LTFU) Phase 1/2a study for subjects with cervical spinal cord injury (SCI) who received AST-OPC1, an oligodendrocyte progenitor cell therapy. The study, involving 25 participants, aims to monitor long-term safety over 15 years post-administration. Completion is expected on January 14, 2033. AST-OPC1 is an investigational regenerative medicine product targeting neurological repair in SCI.
trial completionLineage Cell Therapeutics is conducting a Phase 1b, open-label, multi-center clinical trial to evaluate the safety of a novel delivery device for administering LCTOPC1 in patients with subacute and chronic spinal cord injuries. The study will enroll up to 10 participants and monitor long-term safety for up to 10 years post-administration. The trial is expected to complete on April 27, 2037. LCTOPC1 is an investigational cell therapy product aimed at treating spinal cord injuries.
trial completion